Vertex Pharmaceuticals Incorpor 🇺🇸
VRTX • Technology • USA
⚡ 79.1/100
Wide Moat Score™
$541.69
+0.0% (24H)
Fundamental Snapshot • Market Cap: $137.3B
PEG Ratio
2.28x
EXPANDED
Forward P/E
28.5x
GROWTH FAIR
Revenue Growth YoY
+12.5%
MODERATE
Gross Margin
55.0%
HIGH PRICING POWER
Free Cash Flow
$2.6B
CASH FORTRESS
Debt / EBITDA
0.4x
SOLVENT BALANCE
📊 Proprietary 12-Point Fundamental Audit
| Audit Dimension | Benchmark Criterion | VRTX Actual | Evaluation |
|---|---|---|---|
| 1. Economic Moat Strength | Software lock-in / high switching barrier / patent moat | Moat Score 79.1/100 | ✅ WIDE MOAT |
| 2. Pricing Power & Margins | Gross Margin > 40% sustainable | 55.0% Gross Margin | ✅ PASSED |
| 3. Revenue Acceleration | YoY Top-Line Growth > 15% | +12.5% YoY | ⚠️ IN-LINE |
| 4. Peter Lynch PEG Ratio | PEG < 1.2x (Growth at a Reasonable Price) | 2.28x PEG Ratio | ⚠️ ELEVATED |
| 5. Fortress Balance Sheet | Debt / EBITDA < 2.5x | 0.4x Net Leverage | ✅ PASSED |
| 6. Free Cash Flow Generation | Positive and compounding FCF | $2.6B Free Cash Flow | ✅ PASSED |
| 7. Multiple vs Sector Median | Forward P/E reasonable vs earnings growth | Forward P/E: 28.5x | ✅ ATTRACTIVE MULTIPLE |
| 8. Management & Insider Ownership | Insider Ownership > 3% | 0.2% Insider Equity | ℹ️ INSTITUTIONAL |
| 9. Superinvestor Whale Backing | Held by Top 25 13F Wall St Whales | Institutional Superinvestor Interest | ℹ️ SCREENED |
| 10. Secular Industry Tailwinds | Exposure to multi-year compound themes | Technology sector expansion | ✅ PASSED |
| 11. Trailing P/E Multiple | Historical earnings multiple sanity | Trailing P/E: 31.5x | ✅ PASSED |
| 12. Overall Moat Conviction | Composite algorithmic evaluation | Overall Score: 79.1/100 | ✅ HIGH CONVICTION |
📝 MoatPicks Investment Thesis
Competitive Moat Breakdown: Undisputed leader in cystic fibrosis treatments with expanding pipeline.
Valuation Verdict: Trading at a Forward P/E of 28.5x and PEG ratio of 2.28x, Vertex Pharmaceuticals Incorpor satisfies core fundamental screens for quality and durability.